{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:11:48Z","timestamp":1792512708575,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Complement activation has been reported in primary immune thrombocytopenia (ITP); however, its clinical relevance remains poorly understood. This study aimed to clarify the association between complement activation and various biomarkers and the clinical characteristics of patients with ITP. A total of 40 patients with ITP were enrolled in this study. Platelet-bound C1q, C3d, and C4d were elevated in a substantial population of patients with ITP compared with healthy controls with highly variable titers. Hierarchical clustering analysis showed that patients with ITP could be classified into the following 3 groups according to their levels: all negative (cluster 1), elevated C1q with negative to low C3d and C4d (cluster 2), and high C3d and C4d (cluster 3). Platelet-associated (PA) immunoglobulin M (IgM) was detected mostly in cluster 3, and PA-IgG was detected in clusters 2 and 3. The number of cases refractory to first-line therapy increased in clusters 2 and 3. Complement deposition on the platelet surface correlated with an increased percentage of immature platelets. There was no significant association between complement activation and PA glycoprotein IIb\/IIIa (GPIIb\/IIIa) or PA-GPIb\/IX antibodies, C1s ratio in the plasma, and fatigue score. Our results suggest that PA-IgG and PA-IgM contribute differentially to the complement activation profile on the platelet surface and are associated with increase in platelet turnover, characterizing a distinct subset of patients with ITP with complement activation. Our findings also may provide a rationale for stratifying patients in future clinical trials of complement-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032255","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:06:16Z","timestamp":1774980376000},"page":"2958-2969","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Complement activation profile in adult primary immune thrombocytopenia"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6935-6000","authenticated-orcid":false,"given":"Keiichi","family":"Nakata","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka, Suita, Japan"},{"name":"2Department of Hematology, Suita Municipal Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichio","family":"Onami","sequence":"additional","affiliation":[{"name":"3Translational Research Division, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kato","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka, Suita, Japan"},{"name":"4Department of Blood Transfusion and Cell Therapy, The University of Osaka Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kosugi","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Toyonaka Municipal Hospital, Toyonaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7645-0989","authenticated-orcid":false,"given":"Yoshiaki","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Matsushita","sequence":"additional","affiliation":[{"name":"6Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"},{"name":"7Department of Advanced Clinical and Translational Immunology, Graduate School of Medicine, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Kurata","sequence":"additional","affiliation":[{"name":"3Translational Research Division, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-2356","authenticated-orcid":false,"given":"Kazuki","family":"Sato","sequence":"additional","affiliation":[{"name":"6Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasumi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"8Chugai Research Institute for Medical Science, Inc, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Sawamura","sequence":"additional","affiliation":[{"name":"8Chugai Research Institute for Medical Science, Inc, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[{"name":"3Translational Research Division, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-0566","authenticated-orcid":false,"given":"Shuichi","family":"Ohtomo","sequence":"additional","affiliation":[{"name":"3Translational Research Division, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-0947","authenticated-orcid":false,"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-8667","authenticated-orcid":false,"given":"Hirokazu","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2026061111220689300_bib1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"2026061111220689300_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061111220689300_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"issue":"22","key":"2026061111220689300_bib4","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2026061111220689300_bib5","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"2026061111220689300_bib6","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2026061111220689300_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0037-1963(00)90102-1","article-title":"Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura","volume":"37","author":"McMillan","year":"2000","journal-title":"Semin Hematol"},{"issue":"1","key":"2026061111220689300_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-013-1370-4","article-title":"Pathophysiology and management of primary immune thrombocytopenia","volume":"98","author":"Kashiwagi","year":"2013","journal-title":"Int J Hematol"},{"issue":"5","key":"2026061111220689300_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2141.2003.04509.x","article-title":"The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb\/IIIa in patients with idiopathic thrombocytopenic purpura","volume":"122","author":"Chan","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"2026061111220689300_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2141.1985.tb02987.x","article-title":"Platelet associated immunoglobulins (PAIgG and PAIgM) in autoimmune thrombocytopenia","volume":"59","author":"Hegde","year":"1985","journal-title":"Br J Haematol"},{"issue":"1","key":"2026061111220689300_bib11","first-page":"201","article-title":"Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura","volume":"53","author":"Winiarski","year":"1983","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2026061111220689300_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V59.5.1023.1023","article-title":"Platelet-associated complement C3 in immune thrombocytopenic purpura","volume":"59","author":"Myers","year":"1982","journal-title":"Blood"},{"issue":"4","key":"2026061111220689300_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI111814","article-title":"Platelet antibodies of the IgM class in immune thrombocytopenic purpura","volume":"75","author":"Cines","year":"1985","journal-title":"J Clin Invest"},{"issue":"6","key":"2026061111220689300_bib14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood.V50.6.1129.1129","article-title":"Platelet-bound complement (C3) in immune thrombocytopenia","volume":"50","author":"Hauch","year":"1977","journal-title":"Blood"},{"issue":"3","key":"2026061111220689300_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1056\/NEJM197901183000302","article-title":"Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets","volume":"300","author":"Cines","year":"1979","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061111220689300_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2141.1985.tb07477.x","article-title":"Platelet-associated complement in chronic ITP","volume":"60","author":"Kurata","year":"1985","journal-title":"Br J Haematol"},{"issue":"1","key":"2026061111220689300_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.19070","article-title":"Complement in immune thrombocytopenia (ITP): the role of complement in refractory ITP","volume":"203","author":"Weitz","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"2026061111220689300_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Haematol"},{"issue":"6","key":"2026061111220689300_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2026061111220689300_bib20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"15","key":"2026061111220689300_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061111220689300_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"issue":"14","key":"2026061111220689300_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2026061111220689300_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"2026061111220689300_bib25","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2026061111220689300_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2026061111220689300_bib27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/17474086.2023.2286730","article-title":"Fatigue and health-related quality of life in patients with immune thrombocytopenia: a longitudinal assessment in China","volume":"16","author":"Zhang","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2026061111220689300_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.25348","article-title":"Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent\/chronic immune thrombocytopenia: findings from the EXTEND study","volume":"94","author":"Khelif","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2026061111220689300_bib29","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2012-02-409995","article-title":"Recognition of highly restricted regions in the \u03b2-propeller domain of \u03b1IIb by platelet-associated anti-\u03b1IIb\u03b23 autoantibodies in primary immune thrombocytopenia","volume":"120","author":"Kiyomizu","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2026061111220689300_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12185-015-1741-0","article-title":"Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders","volume":"101","author":"Sakuragi","year":"2015","journal-title":"Int J Hematol"},{"issue":"7","key":"2026061111220689300_bib31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ki.2011.497","article-title":"Pros and cons for C4d as a biomarker","volume":"81","author":"Cohen","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"2026061111220689300_bib32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-017-1470-2","article-title":"Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus","volume":"19","author":"Martin","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2026061111220689300_bib33","doi-asserted-by":"crossref","first-page":"2159019","DOI":"10.1080\/09537104.2022.2159019","article-title":"Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study","volume":"34","author":"Akesson","year":"2023","journal-title":"Platelets"},{"issue":"1-3","key":"2026061111220689300_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/IR:36:1:197","article-title":"Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity","volume":"36","author":"Toapanta","year":"2006","journal-title":"Immunol Res"},{"issue":"5","key":"2026061111220689300_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-3083.2011.02600.x","article-title":"The isotype of autoantibodies influences the phagocytosis of antibody-coated platelets in autoimmune thrombocytopenic purpura","volume":"74","author":"Hoemberg","year":"2011","journal-title":"Scand J Immunol"},{"issue":"4","key":"2026061111220689300_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/imcb.12324","article-title":"Antibody-mediated complement activation in pathology and protection","volume":"98","author":"Goldberg","year":"2020","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"2026061111220689300_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2101196","article-title":"At critically low antigen densities, IgM hexamers outcompete both IgM pentamers and IgG1 for human complement deposition and complement-dependent cytotoxicity","volume":"209","author":"Oskam","year":"2022","journal-title":"J Immunol"},{"issue":"7","key":"2026061111220689300_bib38","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.4049\/jimmunol.177.7.4727","article-title":"Activation of the lectin pathway by natural IgM in a model of ischemia\/reperfusion injury","volume":"177","author":"Zhang","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"2026061111220689300_bib39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","article-title":"Platelet activation leads to activation and propagation of the complement system","volume":"201","author":"Del Conde","year":"2005","journal-title":"J Exp Med"},{"key":"2026061111220689300_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molimm.2019.10.004","article-title":"Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands","volume":"116","author":"Hester","year":"2019","journal-title":"Mol Immunol"},{"issue":"26","key":"2026061111220689300_bib41","doi-asserted-by":"crossref","first-page":"e2102787118","DOI":"10.1073\/pnas.2102787118","article-title":"C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases","volume":"118","author":"Zwarthoff","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2026061111220689300_bib42","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/biom13101522","article-title":"The molecular mechanisms of complement receptor 1-it is complicated","volume":"13","author":"Hardy","year":"2023","journal-title":"Biomolecules"},{"issue":"10","key":"2026061111220689300_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026061111220689300_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.162.1.75","article-title":"Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria","volume":"162","author":"Kinoshita","year":"1985","journal-title":"J Exp Med"},{"issue":"32","key":"2026061111220689300_bib45","doi-asserted-by":"crossref","first-page":"19228","DOI":"10.1016\/S0021-9258(19)47291-8","article-title":"Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex","volume":"264","author":"Sims","year":"1989","journal-title":"J Biol Chem"},{"issue":"5","key":"2026061111220689300_bib46","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1309\/RAW2-0LQW-8YTX-941V","article-title":"Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia","volume":"115","author":"Kurata","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2026061111220689300_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-023-03672-1","article-title":"Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition","volume":"119","author":"Kashiwagi","year":"2024","journal-title":"Int J Hematol"},{"issue":"21","key":"2026061111220689300_bib48","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1182\/blood-2010-11-321398","article-title":"Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia","volume":"117","author":"Barsam","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2026061111220689300_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.13475","article-title":"Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course","volume":"201","author":"Castelli","year":"2020","journal-title":"Clin Exp Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2958\/2525807\/blood_bld-2025-032255-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2958\/2525807\/blood_bld-2025-032255-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:22:18Z","timestamp":1781191338000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/24\/2958\/567491\/Complement-activation-profile-in-adult-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032255","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,11]]},"published":{"date-parts":[[2026,6,11]]}}}